title: [Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].
abstract: Chronic myeloid leukemia (CML) is exceptional amongst neoplasias since its underlying pathomechanism has been elucidated, and potent well tolerated targeted drugs, the tyrosine kinase inhibitors (TKI), are available for treatment. They convincingly improve prognosis while retaining good quality of life. Aims of therapy are complete remissions as well as prolongation of life and cure. Imatinib 400 mg per day is current standard therapy. There are hints for a better outcome with a higher initial imatinib dose or with combination therapy. Even after achievement of complete molecular response continuous therapy might be necessary in most cases. In case of imatinib intolerance or failure, the second generation TKI dasatinib and nilotinib and allogeneic stem cell transplantation are available. The use of second generation TKI as first line treatment might further improve prognosis. The therapeutic response should be regularly monitored according to international recommendations.
authors.affiliation: CML-Studienzentrale, III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Deutschland. armin.leitner@medma.uni-heidelberg.de
authors.forename: A A
authors.initials: AA
authors.lastname: Leitner
authors.forename: R
authors.initials: R
authors.lastname: Hehlmann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005858:Germany; D006405:Hematology / Q000639:trends; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008495:Medical Oncology / Q000639:trends; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D033581:Stem Cell Transplantation / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases